Clinical Characteristics of Chronic Myeloid Leukemia Patients with Deletion and Non-deletion of ASS Gene on Derivative Chromosome 9
10.3971/j.issn.1000-8578.2023.22.0701
- VernacularTitle:慢性髓性白血病衍生9号染色体ASS基因缺失与非缺失患者的临床特征
- Author:
Guanlun GAO
1
;
Xuan ZHOU
;
Na XU
;
Xiaoli LIU
;
Ting WEI
;
Qingshan LI
Author Information
1. Department of Hematology, Guangzhou Red Cross Hospital (The Affiliated Hospital, Jinan University), Guangzhou 510220, China
- Publication Type:Research Article
- Keywords:
Leukemia;
Chronic;
ASS gene;
Imatinib;
Prognosis
- From:
Cancer Research on Prevention and Treatment
2023;50(3):283-287
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical characteristics of patients with chronic myeloid leukemia (CML) in chronic phase with deletion and non-deletion of the argininosuccinate synthesis gene (ASS gene) on the derivative chromosome 9. Methods The clinical data of patients with CML initially treated with imatinib and BCR/ABL1/ASS1 3-color fusion probe to detect ASS gene deletion were analyzed. The patients were divided into deletion group (n=27) and non-deletion group (n=92). Clinical characteristics, treatment effects, and prognosis were analyzed. Results The average age of 119 patients was 37.22±12.72 years old. The sokal score differed between the deletion and non-deletion groups (χ2=4.304, P=0.038). No statistically significant difference in other general characteristics was found (P > 0.05). The 3-month CCyR rate, 6-month CCyR rate, and BCR-ABLIS≤ 1% rate in the deletion group were lower than those in the non-deletion group (P < 0.05). The median follow-up of 119 patients was 35.0 (3.0-60.0) months. The PFS in the deletion group was lower than that in the non-deletion group (χ2=4.293, P=0.038). Overall survival was not significantly different between the two groups (χ2=0.008, P=0.931). Conclusion The deletion of the ASS gene in patients with chronic CML is related to the poor efficacy of imatinib treatment, poor prognosis, and high risk of disease progression.
